Dare Bioscience, Inc. reported on May 1, 2026, the successful closing of its Regulation A offering, issuing 195,010 Investor Units at $5.00 each, comprising Series A Preferred Stock and warrants for a total of 390,020 shares of common stock. This event is significant for the company.